Pharmacologic management of glaucoma in childhood

Pediatric Drugs

Volumn 9, Issue 2, 2007, Pages 71-79

  Moore, Will ^a   Nischal, Ken K ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BENZALKONIUM CHLORIDE; BENZODODECINIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; COMBIGAN; CORTICOSTEROID; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; DUO TRAV; GANFORT; LATANOPROST; LATANOPROST PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL MALEATE; LEVOBUNOLOL; NYOGEL; PILOCARPINE; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; TRAVOPROST PLUS TIMOLOL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALLERGIC CONJUNCTIVITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANIRIDIA; APNEA; AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; ASTHENIA; ASTHMA; BITTER TASTE; BLEPHARITIS; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; BURN; CATARACT; CHEMOSIS; CHILDHOOD DISEASE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA EDEMA; CORNEA TRANSPLANTATION; DEPRESSION; DIZZINESS; DROP ATTACK; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG POTENTIATION; DRUG WITHDRAWAL; DRY EYE; DRY NOSE; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; EYE ALLERGY; EYE BURNING; EYE COLOR; EYE DISCHARGE; EYE DISCOMFORT; EYE DISEASE; EYE INJURY; EYE IRRITATION; EYE PAIN; EYE STINGING; EYEBROW PAIN; EYELID CRUSTING; EYELID DISEASE; EYELID EDEMA; EYELID RETRACTION; FATIGUE; GLAUCOMA; HEADACHE; HEART BLOCK; HEART FAILURE; HEART PALPITATION; HOMOCYSTINURIA; HUMAN; HYPEREMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; HYPOTHERMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRITIS; KERATITIS; LACRIMATION; LENS; LOWE SYNDROME; MARFAN SYNDROME; METABOLIC ACIDOSIS; MYDRIASIS; MYOPATHY; MYOPIA; NAUSEA; NEUROFIBROMATOSIS; OBSTRUCTIVE AIRWAY DISEASE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PAIN; PARESTHESIA; PETERS ANOMALY; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; PUNCTATE KERATITIS; PUPIL DISEASE; RECOMMENDED DRUG DOSE; RETINA MACULA CYSTOID EDEMA; REVIEW; RHINITIS; RIEGER SYNDROME; RUBELLA; SIDE EFFECT; SINUSITIS; STURGE WEBER SYNDROME; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; UROLITHIASIS; URTICARIA; UVEITIS; VITREOUS HEMORRHAGE; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ANTIHYPERTENSIVE AGENTS; CHILD; DRUG APPROVAL; ENGLAND; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE;

EID: 34247235127     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709020-00001     Document Type: Review

References (48)

1. Taylor D, Hoyt C. Paediatric ophthalmology and strabismus. 3rd ed. London: Elsevier Ltd, 2005
2. Francois J. Congenital glaucoma and its inheritance. Ophthalmologica 1980; 181: 61-73
3. Kanski JJ. Clinical ophthalmology: a systematic approach. 5th ed. New York: Butterworth-Heinemann, 2003: 192-269
4. Ho CL, Walton DS. Primary congenital glaucoma: 2004 update. J Pediatr Ophthalmol Strabismus 2004; 41 (5): 271-88
5. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 2000; 44 (5): 367-408
6. Muir KW, Jin J, Freedman SF. Central corneal thickness and its relationship to intraocular pressure in children. Ophthalmology 2004; 111: 2220-3
7. deLuise VP, Anderson DR. Primary infantile glaucoma (congenital glaucoma): review. Surv Ophthalmol 1983; 28 (1): 1-19
8. Boger 3rd WP, Walton DS. Timolol in uncontrolled childhood glaucomas. Ophthalmology 1981; 88 (3): 253-8
9. McMahon CD, Hetherington Jr J, Hoskins Jr HD, et al. Timolol and pediatric glaucomas. Ophthalmology 1981; 88 (3): 249-52
10. Hoskins Jr HD, Hetherington Jr J, Magee SD, et al. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol 1985; 103 (8): 1163-5
11. Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol 1983; 28 (1): 1-19
12. Weinreb RN, Caldwell DR, Goode SM, et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol 1990; 110 (2): 189-92
13. Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97 (1): 86-92
14. Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345 (8970): 1604-6
15. Allen RC, Hertzmark E, Walker AM, et al. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol 1986; 101 (5): 535-41
16. Drance SM. A comparison of the effects of betaxolol, timolol and pilocarpine on the visual function in patients with open-angle glaucoma. J Glaucoma 1998; 7 (4): 247-52
17. British National Formulary. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain, 2005 Sep
18. Michaud J-E, Friren B, International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice a day in addition to timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2001; 132: 235-43
19. Portellos M, Buckley E, Freedman S. Topical versus oral carbonic anhydrase inhibitor therapy for paediatric glaucoma. JAAPOS 1998; 2 (1): 43-7
20. Silver LH, Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide, a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126: 400-8
21. Morris S, Geh V, Nischal K. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol 2003 Aug; 87 (8): 1052-3
22. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999; 127: 403-6
23. Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005 Nov; 21 (11): 1875-83
24. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002; 47 Suppl. 1: S65-76
25. Susanna Jr R, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol 2002; 47 Suppl. 1: S97-104
26. Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol 2002; 47 Suppl. 1: S129-32
27. Ong T, Chia A, Nischal KK. Latanoprost in port wine stain related paediatric glaucoma. Br J Ophthalmol 2003; 87: 1091-3
28. Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 2002; 47 Suppl. 1: S133-40
29. Brown S. Increased iris pigment in a child due to latanoprost. Arch Ophthalmol 1998 Dec; 116 (12): 1683-4
30. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47 Suppl. 1: S203-18
31. Drugs and therapeutics bulletin. The management of primary open angle glaucoma BNF 11.6 1997; 35 (1): 4-6 [online]. Available from URL: http://www.dtb.org.uk [Accessed 2006 Feb 21]
32. Drugs and therapeutics bulletin. New topical drugs for open-angle glaucoma. BNF 11.6 2003 (Feb) [online]. Available from URL: http://www.dtb.org. uk [Accessed 2006 Feb 21]
33. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002; 47 Suppl. 1: S219-30
34. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr 2004; 43 (1): 99-101
35. Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999; 128: 255-6
36. Mungan NK, Wilson TW, Nischal KK, et al. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. JAAPOS 2003; 7 (1): 69-70
37. Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops in children. Eye 2004; 18 (1): 24-6
38. Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005; 112: 2143-8
39. Schwartzenberg GW, Buys YM. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999; 106: 1616-20
40. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998; 105: 1936-44
41. Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with its concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005; 15: 581-90
42. Patton TF, Robinson JR. Pediatric dosing considerations in ophthalmology. J Ped Ophthalmol 1976; 13 (3): 171-8
43. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982; 26: 207-18
44. Passo MS, Palmer EA, Van-Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984; 91 (11): 1361-3
45. Palmer EA. How safe are ocular drugs in pediatrics? Ophthalmology 1986; 93 (8): 1038-40
46. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418-23
47. Baudouin CB, Pisella P-J, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology 1999; 106: 556-63
48. Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108 (11): 1543-8